印度代购提示本品波生坦是内皮素受体拮抗剂这一家族中最先上市的靶向药物，虽然存在一定机率的肝损伤，但是在定期检测下可以较早发现，及时停药或者加用护肝药物可逆转。2018年，波生坦被纳入基本药品目录。

Bosentan is the first targeted drug to hit the market in the family of endothelin receptor antagonists. Although there is a certain probability of liver injury, it can be detected early under regular detection, and it can be reversed by timely discontinuation or addition of liver-protecting drugs. In 2018, Bosentan was added to the List of essential medicines.

波生坦

　　印度代购提示本品肺动脉高压是一种慢性、危及生命的疾病，由于各种心肺疾病或系统性疾病引起肺动脉压力升高，进一步导致右心衰竭，该病的致死率、致残率都很高，严重影响患者的生活质量，预后和某些癌症类似，故有人将其称之为“心血管疾病中的癌症”。在肺动脉高压领域，波生坦是第一个口服内皮素受体拮抗剂，它能降低肺动脉的压力，能缓解右室负荷，改善了患者的生存质量，包括心功能的改善，运动耐量的提高，无疑波生坦进入基本药物目录，将造福于社会，造福于肺动脉高压的患者。

　　印度代购提示本品国家基本药物中所列品种是专家和广大医药工作者从我国临床应用的各类药物中通过科学评价和论证，筛选出来的具有代表性的药物，是能够满足基本医疗卫生需求，剂型适宜、保证供应、基层能够配备、国民能够公平获得的药品。波生坦进入国家基本药物目录标志着一个新的时代的来临，也说明罕见病领域得到了国家及社会的关注，打下了坚实的基础。这意味着国家对肺动脉高压治疗的高度重视，未来将会有更多肺动脉高压患者得到切实可靠的保障。

Varieties are listed in the national essential drug experts and the vast majority of medical workers of all kinds of drugs in clinical application in China through the scientific evaluation and demonstration, screen out the typical drugs, is to be able to meet the demand of basic medical and health care, appropriate, to ensure supply of dosage form, basic unit can be equipped with, national can equitable access to drugs. Bosentan's entry into the National Essential Medicine List marks the advent of a new era, and also indicates that the field of rare diseases has received national and social attention and laid a solid foundation. This means that the country attaches great importance to the treatment of pulmonary hypertension, and more patients with pulmonary hypertension will be guaranteed reliably in the future.